US 12,453,730 B2
Methods of treatment
Sundar Srinivasan, Corona Del Mar, CA (US); and Christina Chow Wallen, La Grange, IL (US)
Assigned to BOW RIVER LLC, Corona Del Mar, CA (US)
Filed by BOW RIVER LLC, Corona Del Mar, CA (US)
Filed on Mar. 21, 2025, as Appl. No. 19/087,148.
Application 17/099,298 is a division of application No. 16/191,351, filed on Nov. 14, 2018, granted, now 10,835,529.
Application 19/087,148 is a continuation of application No. 18/600,372, filed on Mar. 8, 2024.
Application 18/600,372 is a continuation of application No. 18/366,060, filed on Aug. 7, 2023, granted, now 11,974,998, issued on May 7, 2024.
Application 18/366,060 is a continuation of application No. 18/118,911, filed on Mar. 8, 2023, granted, now 11,857,548, issued on Jan. 2, 2024.
Application 18/118,911 is a continuation of application No. 17/949,889, filed on Sep. 21, 2022, granted, now 11,801,245, issued on Oct. 31, 2023.
Application 17/949,889 is a continuation of application No. 17/700,947, filed on Mar. 22, 2022, granted, now 11,491,152, issued on Nov. 8, 2022.
Application 17/700,947 is a continuation of application No. 17/469,628, filed on Sep. 8, 2021, granted, now 11,351,160, issued on Jun. 7, 2022.
Application 17/700,947 is a continuation of application No. 17/407,440, filed on Aug. 20, 2021.
Application 17/469,628 is a continuation of application No. 17/244,065, filed on Apr. 29, 2021, granted, now 11,154,545, issued on Oct. 26, 2021.
Application 17/244,065 is a continuation of application No. 17/150,467, filed on Jan. 15, 2021, granted, now 11,052,077, issued on Jul. 6, 2021.
Application 17/407,440 is a continuation of application No. 17/099,298, filed on Nov. 16, 2020, granted, now 11,123,346, issued on Sep. 21, 2021.
Application 17/150,467 is a continuation of application No. 17/082,902, filed on Oct. 28, 2020, granted, now 11,730,724, issued on Aug. 22, 2023.
Application 17/082,902 is a continuation of application No. 16/408,931, filed on May 10, 2019, granted, now 10,857,144, issued on Dec. 8, 2020.
Application 16/191,351 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Application 16/408,931 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Prior Publication US 2025/0213557 A1, Jul. 3, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/00 (2006.01); A61K 31/397 (2006.01); A61K 31/407 (2006.01); A61K 31/4468 (2006.01); A61K 31/454 (2006.01); A61K 31/4745 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/4995 (2006.01); A61K 31/502 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5383 (2006.01); A61K 31/5395 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2004 (2013.01); A61K 9/4841 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4995 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01)] 25 Claims
 
1. A method of treating a disease or disorder with a tyrosine kinase inhibitor in a patient in need thereof, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
a. discontinuing the strong CYP3A4 inhibitor treatment;
b. delaying administering, for about 3 to about 5 half-lives of the strong CYP3A4 inhibitor after discontinuing the strong CYP3A4 inhibitor treatment, a dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
c. administering the dose of the tyrosine kinase inhibitor that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
wherein the strong CYP3A4 inhibitor is posaconazole, and the disease or disorder is not cancer.